{"id":496321,"date":"2020-07-15T19:46:02","date_gmt":"2020-07-15T19:46:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496321"},"modified":"2020-07-15T19:46:02","modified_gmt":"2020-07-15T19:46:02","slug":"hemophilia-a-patient-population-treatment-algorithm-medical-practices-and-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-patient-population-treatment-algorithm-medical-practices-and-epidemiology-forecast-to-2030_496321.html","title":{"rendered":"Hemophilia A Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030"},"content":{"rendered":"
\"<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘ Hemophilia A Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia A epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.<\/span><\/p>\n

 <\/p>\n

Get FREE sample copy at: <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/hemophilia-a-epidemiology-forecast<\/span><\/strong><\/a><\/p>\n

 <\/p>\n

\"Hemophilia-A-Epidemiology-Forecast<\/a><\/p>\n

The DelveInsight  Hemophilia A epidemiology report gives a thorough understanding of the  Hemophilia A by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for  Hemophilia A in the US, Europe, and Japan. The report covers the detailed information of the  Hemophilia A epidemiology scenario in seven major countries (US, EU5, and Japan).<\/p>\n

 <\/p>\n

Key Highlights Of The Report<\/strong><\/p>\n

Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017. .<\/em><\/p>\n

According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.<\/em><\/p>\n

Among the European 5 countries, the United Kingdom had the highest prevalent population of Hemophilia A, followed by France and Italy.<\/em><\/p>\n

 <\/em><\/p>\n

Hemophilia A Epidemiology<\/strong><\/a><\/p>\n